In addition to advancing our own clinical pipeline in oncology, Cristal Therapeutics has forged a number of strategic partnerships with pharmaceutical and biotechnology companies to co-develop therapeutic nanomedicines and assess their applicability across a number of therapeutic areas.

CPC 634

We plan to partner / out-license CPC634, our lead product candidates after Phase 2 studies to pharmaceutical companies with late stage development and commercialisation capabilities in attractive geographic territories.

Inflammation program

In addition CPC289, the therapeutic asset from our inflammation program is ready for pre-clinical development and is available for out-licensing.